Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine
pharmafile | March 16, 2016 | News story | Research and Development, Sales and Marketing | NSCLC, immuno-oncology, vaxon biotech
Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung cancer (NSCLC).
The company said Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimized cryptic tumor peptides.
Kostas Kosmatopoulos, Vaxon’s chief executive, say: “This immuno-oncology trial is one of the biggest of its kind to be carried out by a small biotech company. Finalizing the study has been extremely satisfying for Vaxon Biotech as it has surpassed many of the expectations for a company of our size. It is a strong sign for the market.”
A total of 220 patients with metastatic NSCLC have now been enrolled in the Phase II trial across 70 European trial centers. The primary endpoint is to assess the benefit of Vx-001 versus placebo on overall survival. Final trial results are expected in the fourth quarter of 2016, the French biotech firm said in a statement.
Vx-001 is the first vaccine to use optimized cryptic peptides and is the only such vaccine in development. Optimized cryptic peptides are universal tumor peptides that, while normally undetected by the immune system, have been modified to optimize their presentation to the immune system so as to induce a powerful anti-tumor immune response.
Following the results of the trial the company will initiate Phase III study in the European Union and the US in 2017.
Vaxon Biotech is aiming to receive marketing authorization for the drug in 2020.
Anjali Shukla
Related Content
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio …
iOnctura expands clinical trial programme for NSCLC
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …
